IDH2 and glioblastoma: A multicenter cohort study of 496 patients with glioblastoma showed IDH mutation in 31 (6.3%)11, limiting the ability of MRI to train a network to reliably predict IDH mutation status. In consequence, most studies seeking to improve the noninvasive identification of this subtype have lacked sufficient statistical power.